Single infusion of zoledronic acid for patients with Paget's disease produces sustained response

摘要

Patients suffering from Paget's disease may benefit from a single infusion of zoledronic acid,say researchers.Current bisphosphonate treatment consists of daily oral dosing for two to six months,and patients are required to fast before and after treatment because of the low bioavailability of the drugs.Intravenous pamidronate is also used but is usually given as a series of slow intravenous infusions requiring multiple visits.However,researchers have found that a single infusion of zoledronic acid can produce a rapid and sustained response and can possibly offer more complete disease control than current therapies.